Targets in early NSCLC: A focus on EGFR-mutant treatment options

touchFOCUS for touchONCOLOGY

Listen to Dr Jennifer Carlisle, an expert in lung cancer, as she answers a series of questions on the targeted perioperative treatment strategies and best practices for patients with resectable and unresectable early-stage EGFR-mutant NSCLC. She also discusses how the evolving treatment landscape impacts biomarker testing and the importance of multidisciplinary care for optimizing outcomes in these patients.

The expert

Dr Jennifer Carlisle, Winship Cancer Institute of Emory University, Atlanta, GA, USA

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.

For further information visit our website: www.touchoncology.org/EGFR-mutant-treatment-options-early-NSCLC